Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB ) study with therapeutic implications
Histopathology, 06/09/09
Llombart B et al. - The COL1A1-PDGFB fusion was present in all histological subtypes of DFSP, but not all cases expressed the fusion transcript. No association was observed between different COL1A1 breakpoints and clinicopathological parameters. Imatinib mesylate can be useful in locally advanced tumours and metastases.
Related Articles
Intracranial infiltration by recurrent scalp dermatofibrosarcoma protuberans
Journal of Clinical Neuroscience, 10/07/09
Relevance Score: 67%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Activating Peroxisome Proliferator-Activated Receptor gamma Mutant Promotes Tumor Growth In vivo by Enhancing Angiogenesis
Cancer Research, 12/20/09
Extracellular Signal–Regulated Kinase Signaling Pathway Regulates Breast Cancer Cell Migration by Maintaining slug Expression
Cancer Research, 12/20/09
hnRNP A2 Regulates Alternative mRNA Splicing of TP53INP2 to Control Invasive Cell Migration
Cancer Research, 12/20/09
Today in Dermatologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions
Human Pathology, 12/19/09
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays
Human Pathology, 12/19/09
Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center
Leukemia and Lymphoma, 12/17/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


